All
Secukinumab superior to etanercept for plaque psoriasis
October 14th 2013Secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was more effective in treating moderate-to-severe plaque psoriasis than the anti-tumor necrosis factor etanercept and current standard of care, according to a head-to-head phase 3 study.
Advanced genetic testing paves way for personalized medicine
October 1st 2013New genetic testing methods may not only help identify the potential risk for individuals to develop certain diseases but may also open the door for more targeted therapies and management strategies, which could be of particular benefit in higher risk patient populations.
Guidelines clarify controversies surrounding vitamin D
October 1st 2013Vitamin D has been in and out of favor with physicians and their patients over the years. Even today, the controversies over the embattled vitamin still continue regarding its safe and beneficial daily allowance. According to the recent research, however, and guidelines from the Institute of Medicine (IOM), the majority of Americans are taking enough vitamin D.
Hyaluronic acid products dominate filler market in Europe
October 1st 2013In the European Union (EU), a simple approval process for hyaluronic acid (HA) products has yielded a broader array of offerings than what’s available in the United States, an expert says. Easier EU approvals also have given HA a virtual lock on the European filler market, he adds.
Dermatologists contribute to overuse of antibiotics
October 1st 2013Dermatologists generally know that the sensitivity of many pathogens to the antibiotics used to treat them is decreasing, experts say. But many dermatologists may not appreciate their specialty’s role in potentially fueling the problem.
FTC can challenge healthcare practice mergers
October 1st 2013Dr. Derm owns 15 dermatology practices. Dr. Skin owns 12 similar practices. Recently a venture capitalist bought all of these practices and merged them as one practice. All of the dermatologists were given a 20-mile, two-year restrictive covenant.